Phase I/II study in cancer patients showcases eClinical effectiveness.
An Article written by IDDI Published in Applied Clinical Trials, February 1, 2022, Volume 31, Issue 1/2.
Complex study designs are fast becoming the norm—but integrated clinical trial technology can make even the more complicated of data collection requirements a breeze.
IDDI worked on a Phase I/II trial for people with cancer who were ineligible for induction chemotherapy.
High risk participants, complex protocol design, and COVID-19 risk mitigation were among the multiple challenges faced by the sponsor, but all were overcome thanks to the utilization of a range of eClinical tools.
In this case study, the writer looks at how integrated eClinical tools can accelerate study implementation, help to determine a recommended dose safely and accurately, and reduce burden on site staff. He will also look at how to foster effective collaborative partnerships with clinical monitoring teams during a study
Written by Serge Bodart, MS, Chief Commercial Officer, IDDI. Published in Applied Clinical Trials, February 1, 2022, Volume 31, Issue 1/2.
